Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus - Covid 19 Information Sharing Forum -- Ignore unavailable to you. Want to Upgrade?

To: Thomas M. who wrote (4479)	8/7/2023 1:36:39 PM
From: Thomas M.	Read Replies (1) \| Respond to of 5931

Maraviroc isn't only for Covid Long Haulers. It very likely would help against acute Covid. When Bruce Patterson came down with Covid, he preemptively took Maraviroc for a month. CCR5 is a cytokine that directs monocytes toward a site of infection. Maraviroc and Leronlimab are CCR5 antagonists. They block monocytes from binding to and inflaming the endothelial cells on the blood cells. Bruce Patterson initially worked with Leronlimab. Unfortunately, the company that owned Leronlimab had previous trouble with regulators, and the regulators signaled that they were going to obstruct progress, so Patterson moved on to Maraviroc. But there is every reason to think Leronlimab would work well. This tiny trial showed great results. All 10 patients were terminally ill. 6 out of 10 survived. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14 ncbi.nlm.nih.gov Objective Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic. Emerging results indicate a dysregulated immune response. Given the role of CCR5 in immune cell migration and inflammation, we investigated the impact of CCR5 blockade via the CCR5-specific antibody leronlimab on clinical, immunological, and virological parameters in severe COVID-19 patients. Methods In March 2020, 10 terminally ill, critical COVID-19 patients received two doses of leronlimab via individual emergency use indication. We analyzed changes in clinical presentation, immune cell populations, inflammation, as well as SARS-CoV-2 plasma viremia before and 14 days after treatment. Results Over the 14-day study period, six patients survived, two were extubated, and one discharged. We observed complete CCR5 receptor occupancy in all donors by day 7. Compared with the baseline, we observed a concomitant statistically significant reduction in plasma IL-6, restoration of the CD4/CD8 ratio, and resolution of SARS-CoV2 plasma viremia (pVL). Furthermore, the increase in the CD8 percentage was inversely correlated with the reduction in pVL (r = -0.77, p = 0.0013). Tom